Endoscopic Ultrasound System (EUS) segmentation by application distinguishes three principal categories: diagnostic, therapeutic, and combined diagnostic‑therapeutic procedures. The diagnostic segment, accounting for roughly 55 % of total EUS revenue, is driven by the need for high‑resolution imaging in pancreatic, biliary, and gastrointestinal lesion detection. Its market contribution is amplified by increasing cancer screening programs and reimbursement policies favoring early diagnosis. The therapeutic segment, representing about 30 % of the market, includes EUS‑guided fine‑needle aspiration, drainage, and ablative interventions; growth is propelled by minimally invasive treatment adoption and expanding clinical indications such as cystic lesion management. The combined segment, roughly 15 % of sales, integrates imaging and interventional capabilities within a single platform, appealing to high‑volume tertiary centers seeking workflow efficiency. Collectively, these application categories shape the overall EUS market size by allocating capital investment, R&D focus, and sales strategies according to clinical demand patterns. These proportions also guide manufacturers in tailoring product portfolios and pricing models to align with the revenue potential of each application niche.
